Academic Journal
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
| العنوان: | Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. |
|---|---|
| المؤلفون: | Howell, Anthony, Cuzick, Jack, Baum, Michael, Buzdar, Aman, Dowsett, Mitch, Forbes, John F, Hoctin-Boes, G, Houghton, Joan, Locker, Gershon, Tobias, J S |
| المساهمون: | Christie Hospital, Manchester, UK. anthony.howell@christie-tr.nwest.nhs.uk |
| سنة النشر: | 2005 |
| المجموعة: | The Christie School of Oncology: Christie Research Publications Repository |
| مصطلحات موضوعية: | Breast Cancer, Oestrogen Antagonists, Cancer Metastasis, Cancer Recurrence, Antineoplastic Agents, Hormonal, Antineoplastic Combined Chemotherapy Protocols, Aromatase Inhibitors, Breast Neoplasms, Chemotherapy, Adjuvant, Disease-Free Survival, Estrogen Antagonists, Female, Follow-Up Studies, Humans, Neoplasm Metastasis, Neoplasm Recurrence, Local, Nitriles, Postmenopause, Randomized Controlled Trials as Topic, Survival Rate, Tamoxifen, Triazoles |
| الوصف: | The standard adjuvant endocrine treatment for postmenopausal women with hormone-receptor-positive localised breast cancer is 5 years of tamoxifen, but recurrences and side-effects restrict its usefulness. The aromatase inhibitor anastrozole was compared with tamoxifen for 5 years in 9366 postmenopausal women with localised breast cancer. After a median follow-up of 68 months, anastrozole significantly prolonged disease-free survival (575 events with anastrozole vs 651 with tamoxifen, hazard ratio 0.87, 95% CI 0.78-0.97, p=0.01) and time-to-recurrence (402 vs 498, 0.79, 0.70-0.90, p=0.0005), and significantly reduced distant metastases (324 vs 375, 0.86, 0.74-0.99, p=0.04) and contralateral breast cancers (35 vs 59, 42% reduction, 12-62, p=0.01). Almost all patients have completed their scheduled treatment, and fewer withdrawals occurred with anastrozole than with tamoxifen. Anastrozole was also associated with fewer side-effects than tamoxifen, especially gynaecological problems and vascular events, but arthralgia and fractures were increased. Anastrozole should be the preferred initial treatment for postmenopausal women with localised hormone-receptor-positive breast cancer. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1474-547X |
| Relation: | Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer., 365 (9453):60-2 Lancet; http://hdl.handle.net/10541/76533; Lancet |
| DOI: | 10.1016/S0140-6736(04)17666-6 |
| الاتاحة: | http://hdl.handle.net/10541/76533 https://doi.org/10.1016/S0140-6736(04)17666-6 |
| رقم الانضمام: | edsbas.696D96AE |
| قاعدة البيانات: | BASE |
| تدمد: | 1474547X |
|---|---|
| DOI: | 10.1016/S0140-6736(04)17666-6 |